相关实验视频
Updated: Jun 27, 2026
04:41
Knee Arthrocentesis in Adults
Published on: February 25, 2022
7.4K
治疗模式在多关节性青少年异常性关节炎:一个回顾性的观察健康索赔数据研究研究数据研究
Gerd Horneff1,2, Julia Borchert3, Joanna Diesing3
1Department of General Paediatrics, Asklepios Clinic Sankt Augustin, 53757 Sankt Augustin, Germany.
Life (Basel, Switzerland)
|June 27, 2024
概括
新诊断的多关节性青少年异常性关节炎 (polyJIA) 患者在接受常规合成疾病修饰性抗风湿药物 (csDMARDs) 和生物疾病修饰性抗风湿药物 (bDMARDs) 中出现延迟. 许多polyJIA患者仍然未得到充分治疗,不符合强化治疗的指导方针建议.
科学领域:
- 类风湿病学 类风湿病学
- 儿科 儿科 儿科
- 药理学 药理学是指药理学的学科.
背景情况:
- 不活跃性疾病对于最大限度地减少多关节性青少年异常性关节炎 (polyJIA) 的长期关节损伤至关重要.
- 了解治疗时间表和药物调整对于优化多JIA管理至关重要.
研究的目的:
- 描述发生多JIA的患者初始治疗和随后的药物改变的平均时间.
- 在三年内评估纵向和横截面的药物升级模式.
主要方法:
- 从InGef和WIG2纵向健康声明数据库中对发生多重JIA患者的回顾性分析.
- 药物升级水平的评估:没有治疗,葡萄糖皮质类药物 (GCs) /非类固醇抗炎药物 (NSAIDs),常规合成疾病修饰性抗风湿药物 (csDMARDs) 和生物疾病修饰性抗风湿药物 (bDMARDs) 超过三年.
主要成果:
- 刚诊断出多发性JIA的患者在~128天开始服用csDMARD,在~327天开始服用bDMARD.
- 在诊断时,很大一部分患者没有接受JIA治疗 (24%InGef,12%WIG2). 三年后,45% (InGef) 和31% (WIG2) 仍未接受治疗,而bDMARD使用量增加.
- bDMARDs通常持续三年,有时会转换或停止使用. 与组合疗法相比,当csDMARDs作为单一疗法使用时,服用时间更长.
结论:
- 很大一部分多性JIA患者没有接受与当前临床指导方针一致的治疗强度.
- 治疗延迟和治疗不足的模式突出显示了多JIA护理途径中的潜在差距.
相关概念视频
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...